CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life.

is an investigational engineered oncolytic immunotherapy (OIT). It is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy has not been established. In BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with other therapies in clinical trials.

CG Oncology by the Numbers

Based on interim data at the AUA annual meeting 2024, Phase 3 BOND-003 study of cretostimogene grenadenorepvec in monotherapy for patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC):

%

of patients evaluable for efficacy (n=79/105) have achieved complete response (CR) at any time 

%

Durability of Response (DOR) in n=29 patients at 12 months (all ongoing**)

%

of repeat induction patients converted to CR

%

cystectomy-free survival achieved; none of the patients with CR have undergone radical cystectomy and no nodal or metastatic progression
Cretostimogene grenadenorepvec was generally well-tolerated with the most common treatment-related adverse events reported include transient grade 1-2 local genitourinary symptoms. No Grade 3 or higher adverse events related to cretostimogene grenadenorepvec were observed.
*Efficacy cutoff as of 1st April 2024, safety data cutoff as of 31st January 2024
**Median DOR has not been reached and exceeds 9 months

Latest Company News